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digitalis glycosides overdose
Koen R. Maesa, Pieter Depuydtb, Joris Vermassenb, Peter De Paepe c, Walter Buylaert c 
and Cathelijne Lyphoutc
aDepartment of Internal Medicine, Ghent University Hospital, Ghent, Belgium; bDepartment of Intensive Care, Ghent University Hospital, 
Ghent, Belgium; cDepartment of Emergency Medicine and Clinical Toxicology, Ghent University Hospital, Ghent, Belgium
ABSTRACT
We report a case of a 19-year-old woman who ingested Digitalis purpurea leaves as a suicide 
attempt. She developed gastro-intestinal symptoms, loss of colour vision, cardiac conduction 
disturbances as well as an elevated serum potassium. Treatment was initiated in analogy to 
medicinal digoxin poisoning by means of digoxin-speci"c Fab-fragments with a good e#ect. 
However during the further course we faced di$culties of prolonged intestinal absorption and 
inability to estimate the ingested dose or half-life of the vegetal cardiac glycoside compounds. 
To prevent further absorption and interrupt enterohepatic recycling, multi-dose activated 
charcoal was administered. Because of a relapse of cardiac conduction disturbances and 
hyperkalemia, two supplementary doses of Fab-fragments were given, up to a total dose of 
nineteen vials (one vial containing 40 mg). The important diagnostic and therapeutic di#er-
ences of vegetal digitalis intoxication as compared to medicinal intoxication and the applic-
ability of existing guidelines on medicinal digitalis intoxication in the light of these di#erences 
will be discussed here.
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Background
Reports on poisoning with the foxglove plant (Digitalis 
purpurea) are scarce compared to those with digitalis 
glycosides in medicinal form. Accidental foxglove poi-
soning is infrequent because of its bitter taste and 
generally distinct appearance. However, there are 
reports of mistaking foxglove for edible plants like 
comfrey, resulting in the ingestion under the form of 
preparations ranging from tea to stew and even ravioli 
containing digitalis [1–3]. Intentional poisoning with 
the plant has only rarely been reported [4,5]. 
Literature on the practical approach of digitalis glyco-
side poisoning is scarce.
Case presentation
A 19-year-old biology student presented to the emer-
gency department at 7 PM. She had a history of mental 
illness with suicidal ideations but no previous suicide 
attempts. One hour prior to presentation, while return-
ing home from a lecture at the university, she noticed 
a foxglove plant at the side of the road. Aware of its 
toxic properties, she had picked and ingested an esti-
mated total of 20 leaves. After arrival at home, she 
immediately informed her mother and both rushed 
to the regional hospital. Upon initial examination by 
the admitting physician, she looked pale and was per-
spiring but showed no other abnormal clinical signs. 
She denied co-ingestion of other substances. The phy-
sical examination revealed a slow but regular heart 
rate of 40 bpm with a normal blood pressure and no 
signs of circulatory problems. Shortly after admission, 
she reported abdominal pain and experienced nausea 
with vomiting. In addition, she mentioned experien-
cing a blurry vision and a marked reduction of colour 
vision.
Emergency department approach and referral
An electrocardiogram (ECG) showed a sinus rhythm 
(40 bpm) with a second-degree atrioventricular (AV) 
block (Mobitz type I), a marked concavity of the 
depressed ST-segment in the inferolateral leads with 
an inverted T-wave (Figure 1). A blood analysis showed 
an elevated serum potassium of 7 mEq/L (normal 
range 3.5–5.1 mEq/L) and a reduced serum bicarbo-
nate of 19 mEq/L (normal range 22–26 mEq/L). Plasma 
lactate was slightly elevated at 1.54 mmol/L (normal 
range < 1.25 mmol/L).
She was treated with 10 ml of a glucose 30% solu-
tion with 10 IU of rapidly acting insulin intravenously 
(IV) and as well as an aerosol of salbutamol 5 mg/1 ml 
in 2 ml of NaCl 0,9% solution by inhalation to lower the 
serum potassium. For the nausea, she was given 50 mg 
of alizapride and 4 mg of ondansetron IV. One milli-
gram of atropine was administered IV for an episode of 
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bradycardia of 35 bpm (with a normal blood pressure). 
A short episode of a sinus tachycardia of 122 bpm with 
normal PR duration occurred, followed by a relapse of 
the second-degree AV block (30–40 bpm) after 10 min-
utes. The patient was transferred to the intensive care 
unit (ICU) of the university hospital for further follow- 
up and treatment.
ICU admission
Upon arrival at 10 PM, the nausea had slightly 
improved. Her consciousness remained fully pre-
served and there was spontaneous improvement 
of the colour vision. ECG monitoring showed 
a continuous bradycardia of 30–40 bpm with a sec-
ond degree AV block, varying between Mobitz 
types I and II. On arterial blood gas, she had 
a mild compensated metabolic acidosis (pH 7.44 – 
PCO2 28 mm Hg – bicarbonate 19 mEq/L) and 
a persistently elevated serum potassium of 7.1 
mEq/L. A digoxin assay was repeated awaiting the 
results from the "rst assay in the referring hospital, 
showing an unexpectedly low digoxine level of 
0.31 µg/L (therapeutic range between 1–2 µg/L).
All available vials of digoxin-speci"c Fab fragments 
(DigiFab®) were administered at 2 AM, amounting to 
a total dose of 280 mg (7 vials). The manufacturer 
recommends 20 vials (800 mg) in case of acute inges-
tion with an unknown amount of digoxin, but no 
dosage is recommended for vegetal intoxication [6]. 
Meanwhile the pharmacists contacted other hospitals 
in the region and also the Belgian poison centre to 
obtain additional vials.
Between 2 and 8 AM, there was a drop in serum 
potassium to 4.7 mEq/L with the ECG showing a "rst- 
degree AV block mere minutes after administration of 
the Fab fragments. By 8 AM, the second-degree AV 
block reoccurred as well as a rise in serum potassium 
to 6.15 mEq/L (Figure 2). Furthermore, the nausea wor-
sened and resulted in vomiting of greenish vegetal 
material, possibly containing undigested foxglove 
leaves. Therefore, after protection of the airway with 
endotracheal intubation - because of protracted vomit-
ing -multiple doses of activated charcoal (MDAC) were 
administered with an initial dose of 50 g followed by 
20 g every four hours. At 11 AM, 7 supplementary vials 
of Digifab (280 mg) had arrived and were administered. 
This resulted again in a normalization of both the car-
diac rhythm (50 bpm with signs of a "rst-degree AV 
block) and serum potassium (4.9 mEq/L). The second- 
degree AV block reoccurred after 30 minutes. Because of 
a persistent second-degree AV block and bradycardia, 5 
more vials of Digifab® (200 mg) were given at 3 PM. 
Before the third administration, serum potassium was 
no longer elevated (4 mEq/L) (Figure 2).
After 24 hours of MDAC, the administration of acti-
vated charcoal was stopped and the patient was extu-
bated after veri"cation by nasogastric aspiration that 
no gastric residue was left. After regaining conscious-
ness, she was asymptomatic. ECG monitoring showed 
a persistent second-degree AV block without signi"-
cant bradycardia. After a total of four days in the ICU, 
she was transferred to a critical cardiac unit for 
a further 7 days of monitoring. The second-degree AV 
block persisted up to 7 days after intoxication but no 
other arrhythmias were observed.
Figure 1. Time course of the ECG findings. a. 7 PM. ECG at presentation in the referring hospital, showing a second degree AV block 
Mobitz type I with a ventricular rate of 39 bpm. b. 8.30 PM. ECG after administration of 1 mg of atropine intravenously, showing 
a sinus tachycardia of 122 bpm with normal PR duration. c. 10.20 PM. ECG after transfer to the university hospital, showing a second 
degree AV block Mobitz type I, with ventricular rate of 73 bpm. d. 3.41 AM. ECG after a first administration of Fab-fragments a 02 am 
(280 mg), showing a sinus rhythm of 55 bpm with first degree AV block (PR interval 286 ms, normal 120–200 ms). e. 8.06 AM. Six hours 
after the administration of Fab-fragments. Relapse of second degree AV block with 3:1 AV conduction. Ventricular rate of 38 bpm. 
f. 11.30 AM. Thirty minutes after second administration of Fab-fragments. Sinus rhythm of 96 bpm with short PR of 108 ms (normal 
120–200 ms). g. 10.30 PM on day 2. Relapse second degree AV block. Ventricular rate 48 bpm.
2 K. R. MAES ET AL.
Figure 2. Time course of the serum potassium levels. The fine arrow indicates administration of insulin-glucose solution and use of 
a salbutamol nebulizer. The thick arrows indicate administration of Fab-fragments. The characters c-d-e-f-g indicate the respective 
timing of the ECG in.Figure 1
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Discussion
The foxglove plant contains digitalis glycosides, also 
named cardiac glycosides, because of their known 
e#ect on cardiac rhythm and function. These com-
pounds have an inhibitory e#ect on the sodium- 
potassium membrane pump (Na+-K+-ATPase) with 
intracellulair retention of Na+, and a secondary poten-
tiation of calcium in*ux by the sodium-calcium 
exchanger. This results in a build-up of calcium in the 
sarco-endoplasmic reticulum of the cardiac muscle 
cell, which is released in the cytoplasm upon depolar-
ization. This causes a stronger troponin-tropomyosin 
cross-bridging and consequently a more forceful con-
traction. In acute exposures, hyperkalemia is the hall-
mark of cardiac glycoside poisoning. The negative 
chronotropic e#ect is caused by a prolongation of the 
refractory phase in the AV node cells and an increase in 
vagal nerve activity, among other possible e#ects [7]. 
This explains why an overdose can cause both conduc-
tion disorders and life-threatening tachy-arrhythmias 
[8,9]. Other common signs of intoxication include gas-
tro-intestinal symptoms like anorexia and vomiting. 
Vision disturbance and color blindness are typical and 
are caused by a retrobulbar neuritis of the optic nerve. 
Neurological symptoms such as dizziness, confusion 
and convulsions also occur [8,10]. The most common 
and important biochemical hallmarks are an elevation 
of serum potassium (caused by inhibition of the inward 
*ux into the cells) and an accompanying metabolic 
acidosis. ECG "ndings are quite characteristic and 
include a downsloping ST segment depression, shor-
tened QT and widened PR-intervals. These changes 
may suggest the diagnosis in case of an intoxication 
with an unknown substance, but do not correlate with 
toxicity as they are also often seen in patients with 
therapeutic digoxin levels. Moreover, toxic manifesta-
tions and arrhythmias may occur even in the absence 
of these ECG changes [10].
There are important pharmacokinetic di#erences 
between cardiac glycosides with regard to the degree 
of protein binding, lipid solubility and biotransforma-
tion. Digoxin and digitoxin have been used for medic-
inal purposes. The preference for digoxin in 
therapeutic use is because of its relatively short half- 
life of 40 hours, low protein binding and renal excre-
tion with little biotransformation or enterohepatic 
cycling. These factors make digoxin the most predict-
able compound in terms of obtaining therapeutic 
serum concentrations [11].
Cardiac glycosides can be found in several plant 
leaves, *owers and seeds. These plants include but 
are not limited to foxglove (Digitalis purpurea), 
Digitalis lanata, lily of the valley (Convallaria majalis), 
oleander (Nerium oleander), yellow oleander (Thevetia 
peruviana), Strophanthus kombe, squill (Urginea mar-
itima/sea onion/indica bulbs), dogbane (Apocynum 
cannabinum), and Adonis vernalisare [12]. It is impor-
tant to realize that these plants contain not one but 
many di#erent compounds with cardiac glycoside 
e#ects, such as digoxin, digitoxin, digitoxigenin and 
digoxigenin [13]. Many of these compounds have com-
plex pharmacokinetic properties with entero-hepatic 
recirculation and biotransformation to active metabo-
lites (including digoxin) and are eventually excreted by 
the kidneys. These characteristics result in a long 
plasma half-life of up to seven days [11]. The exact 
composition of these plants is known to be highly 
variable due to seasonal di#erences and genetic di#er-
ences [13]. With regard to pharmacodynamics, the 
inotropic e#ects of di#erent Digitalis purpurea leaf 
compounds have been compared by Lüllman et al. in 
animal studies, showing an almost equal inotropic 
dose-e#ect relationship for digoxin and digitoxin but 
other compounds such as digitoxigenin were shown to 
be even more potent. It is unknown whether these 
di#erences correlate with the risk of arrhythmias [14].
Many digoxin assays have been developed for the 
purpose of therapeutic drug monitoring [15,16]. These 
assays are primarily designed for the detection of 
digoxin and there is highly variable cross interference 
with other cardiac glycosides. This explains the discre-
pancy of the measured levels between the referring 
and our hospital. The former used the immunoassay of 
Roche® with a reported cross reactivity for digitoxin of 
1.18% while the latter used the ARCHITECTi Digoxin 
assay of Abbott®, which has a cross reactivity for digi-
toxin of only 0.3%. Likewise, the cross reactivity of 
digitoxigenin for example also di#ers greatly between 
those assays namely 0.18% versus 0.3% [15,16]. 
Therefore, although in many case reports digoxin 
assays are used [1–5], these assays are not designed 
for determining the amount of ingestion in intoxica-
tions other than medicinal [15,16]. They can be used 
for qualitative purposes, but caution is also needed 
due to false negatives which was almost the case in 
our patient [8].
Since vegetal cardiac glycoside intoxications are rare, 
practical guidelines have not been established, in con-
trast with medicinal overdoses of digitoxin and digoxin 
for which recommendations are available. According to 
these recommendations, the "rst step after establishing 
a diagnosis and excluding co-ingestion is to carry out 
a risk evaluation. Dally et al. studied 179 cases of med-
icinal digitoxin intoxication and proposes sex, age, pre-
sence of AV block and plasma potassium concentration 
as the main prognostic factors for mortality. In his study, 
male patients older than 55 years with an AV block and 
a plasma potassium higher than 4.5 mEq/L showed the 
highest mortality (i.e. 74%) in contrast to young females 
without AV block or high potassium who showed 
a mortality of 2% [8,17]. The earlier mentioned risk 
factors are largely in accordance with the guidelines 
for the administration of digoxin-speci"c Fab fragments 
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as an antidote for medicinal overdose (Table 1) [6]. Fab 
fragments are manufactured from immunoglobulins of 
immunized sheep and bind digoxin with a higher a$-
nity than its cardiac receptor, resulting in lower receptor 
binding [6,8]. The Fab-digoxin complexes are cleared by 
either the kidney or the reticuloendothelial system. Fab- 
fragments reduce the free plasma digoxin concentra-
tion, though digoxin assays will show an initial increase 
because the usual assays do not distinguish between 
bound and unbound cardiac glycoside, making these 
assays inadequate for response evaluation in any case of 
intoxication [6,15,16]. Fab-fragments are considered 
safe and have very few side-e#ects. It is however impor-
tant to mention the risk for low potassium level upon 
administration of Fab fragments, de"nitely in combina-
tion with other potassium lowering measures [8]. There 
are two commercially available preparations: DIGIBIND 
(38 mg/vial; GlaxoSmithKline Inc.) and DigiFab (40 mg/ 
vial; BTG, Inc.). Though the dosage in milligram is di#er-
ent, a single vial of both DIGIBIND and DigiFab will bind 
0,5 mg of digoxin in vivo. Therefore, the clinical claims, 
dose recommendations (in vials) and administration of 
these preparations are identical [18]. For this reason, 
many authors mention an amount of vials rather than 
a dosage in milligrams.
The use of Fab-fragments in vegetal cardiac glyco-
side poisoning has been shown to be e#ective in case 
reports but it remains di$cult to determine the opti-
mal dosage [8,19]. There was a frequent need for 
repeat dosing amounting to a total dose of 10 up to 
37 vials [1–3,5]. An initial dose of 20 vials is suggested 
by the manufacturer. Other sources suggest between 
10 and 20 vials as a starting dose, with increasing dose 
should symptom resolution be incomplete [20]. The 
need for a higher dose of the Fab-fragments may be 
due to either pharmacokinetic di#erences between 
cardiac glycosides and the inability to quantify the 
body burden adequately. We could not "nd studies 
that report the a$nity of FAB fragments for cardiac 
glycosides other than digoxin. A factor that should also 
be considered is prolonged absorption as presumably 
occurred in our patient. Absorption from vegetal mate-
rial is less predictable than of medicinal digoxin pre-
parations and prolonged absorption of glycosides 
from an undigested reservoir in the gastro-intestinal 
tract is possible. Bearing in mind that the half-life of the 
Fab-fragments is relatively short (i.e. about 15 hours), 
the delayed absorption may exceed this time [6].
It is recommended to monitor all patients with poten-
tial ingestion of digoxin at least eight hours and transfer 
them to an ICU department [8]. Previously it was reported 
that severe toxicity may not occur until 24 h post- 
admission for digoxin, or up to 5 days for digitoxin 
poisonings [7]. For medicinal digoxin it is stated that if 
the patient remains asymptomatic, the ECG does not 
show any brady- or tachyarrhytmias and potassium is 
within the reference range, the risk of developing signi"-
cant poisoning is low. The recommended eight-hour 
time-window cannot be extrapolated to vegetal cardiac 
glycosides, as serious dysrhythmias may develop up to 
92 hours after ingestion [7].
Decontamination by means of gastric lavage is 
advocated by some although there is little evidence 
to support it. In general, it is not recommended since it 
could delay the use of activated charcoal, which is 
likely more e#ective when prolonged absorption is 
expected [7]. Oral activated charcoal has been 
shown to reduce the digoxin serum concentration in 
acute medicinal poisoning, when given within the "rst 
two hours after ingestion [8,19]. Whether prolonged 
gastro-intestinal absorption in vegetal intoxication 
makes later administration useful is unproven since 
a lot of cases regard accidental poisoning of an extract 
or preparation (e.g. tea of stew) and di#erences in the 
preparations probably change the bio-availability [1– 
3]. If a prolonged absorption is to be expected, for 
example after eating raw plant leaves, activated char-
coal might still be considered even beyond the two- 
hour window. It may then be administered in 
a multiple dose charcoal regimen (MDAC) to addi-
tionally interrupt enterohepatic cycling of toxins, to 
assist elimination, based on pharmacokinetic data [7]. 
Theoretically, whole-bowel irrigation could be con-
sidered for undigested plant residues, but this has not 
been described in case reports. Since digoxin is only 
poorly dialyzable, extracorporeal removal techni-
ques for medicinal overdosing are not useful [8]. 
Other cardiac glycosides than digoxin as present in 
for example Digitalis purpurea have a higher fat solu-
bility and a higher distribution volume, so it can be 
assumed that removal with dialysis will be even less 
e$cient with a higher chance of rebound after dialysis. 
Dialysis may still be considered to treat serious hyper-
kalemia or metabolic acidosis [8].
Correction of potassium by other methods than Fab- 
fragment administration remains dubious since it is 
unclear which potassium concentration is safest in terms 
of arrhythmias [8,20]. In case of severe hyperkalemia, 
insulin-glucose or sodium bicarbonate can be used. In 
an animal model, dextrose seemed to be cardioprotective 
in digoxin toxicity. Use of calcium is dissuaded because it 
Table 1. Indications for the administration of Fab-fragments 
for medicinal intoxication according to the manufacturer, with 
additions from Goldfrank in italic [6,20].
Indications for the administration of Fab-fragments for medicinal 
overdose of digoxin
Severe ventricular arrhythmias, progressive bradycardia, and second or 
third degree heart block with insufficient response to atropine. Any 
glycoside related life threatening dysrhythmia.
Serum potassium levels exceeding 5.5 mEq/L in adults or 6 mEq/L in 
children, especially in case of impaired renal function
High digoxin levels > 10 µg/L
High age, renal, cardiac or hepatic comorbidity 
Poisoning with cardiac glycosides other than digoxin (these include 
vegetal intoxication)
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may potentiate the cardiac e#ects with disastrous conse-
quence. A low serum potassium might however potenti-
ate the e#ect of cardiac glycoside toxicity and should be 
corrected. As mentioned before, potassium levels should 
be monitored after administration of Fab-fragments since 
reinstitution of the Na+/K+ exchange can cause profound 
hypokalemia [20]. Anti-arrhythmic drugs have only 
a limited and short-lived e#ect when compared to Fab- 
fragments so repeated dosages or continuous adminis-
trations of the former are needed. Phenytoin reverses the 
AV conduction prolongation and can terminate supraven-
tricular dysrhythmias other than atrial *utter or "brillation. 
Lidocaine has been used for the same purpose. Atropine 
can be useful to block the vagotonic e#ects in supraven-
tricular brady-arrhythmias. Propranolol and procainamide 
should be avoided due to the risk of depression of cardiac 
conduction [8,20]. Magnesium sulfate has proven useful 
for tachy-arrhythmias even with elevated magnesium 
levels. Hypomagnesaemia should be avoided since it 
increases cardiotoxicity in a similar manner as hypokale-
mia [20]. Cardiac pacing, either transvenous or transcu-
taneous, is contra-indicated because of the risk of pacing- 
induced arrhythmias and lack of reduction in mortality 
when compared to Fab-fragments [8,21]. Electrical cardi-
oversion is generally ine#ective, and should be reserved 
for cases with ventricular dysrhythmias refractory to other 
treatments using low energy levels (e.g. 20–100 J) [7].
Other general supportive measures include ade-
quate emesis control to reduce vagal stimulation and 
maintaining hydration and renal output since excre-
tion is primarily renal.
When above literature data are considered, our 
patient belonged to a high-risk group with 
a mortality risk amounting to 17% in view of the pre-
sence of a cardiac conduction disorder and an elevated 
serum potassium [17]. Consequently, there was an 
indication for the administration of Fab-fragments. 
Pending availability, she received atropine because of 
a low heart rate, which only had a very short-lived 
e#ect. Reducing the serum potassium level with glu-
cose-insulin probably also had limited e#ect. In con-
trast, administration of Fab-fragments resulted in a fast 
correction of the serum potassium and rapid improve-
ment of cardiac conduction disturbances.
In hindsight, earlier administration of MDAC, in this 
case started after a delay of 12 hours, potentially could 
have prevented prolonged absorption from vegetal 
material that proved to still be present in the gastro- 
intestinal tract. A reason for the delay of MDAC was 
that this implicated intubation to ensure a safe airway 
and was therefore considered quite invasive. Seen the 
serious symptoms and expensive treatment with Fab- 
fragments, avoidance of absorption with reduction of 
poisoning is preferable over treatment with Fab- 
fragments solely. The second and third administration 
of Fab-fragments, respectively seven vials (11 hours 
after the "rst dose) and "ve vials (16 hours after), was 
given according to the availability, ECG "ndings and 
hyperkalemia, as no clear guidelines exist for this par-
ticular situation. It is unclear whether the administra-
tion of MDAC lowers risk of mortality or reduces the 
total dose of Fab-fragments needed.
Summary and conclusion
This case of ingestion of Digitalis purpurea as a suicide 
attempt posed no diagnostic problem because of 
a clear history and compatible ECG "ndings. 
However, cardiac glycoside poisoning by plants or 
plant extracts entails some important therapeutic par-
ticularities as opposed to medicinal overdosing.
Firstly, the use of digoxin assays in intoxications 
other than medicinal digoxin overdose is inaccurate 
and misleading because of highly variable cross- 
detection of the variety of cardiac glycosides present 
in plants [15,16]. Secondly, the various cardiac glyco-
sides in plants show di#erences in terms of pharmaco-
kinetics [11]. Absorption from a vegetal source is less 
predictable than a medicinal preparation and metabo-
lism and excretion also greatly di#er between cardiac 
glycosides, resulting in much longer plasma half-lives 
than medicinal digoxin [11]. Multiple dose activated 
charcoal (MDAC) should be considered even beyond 
the two-hour timeframe of single dose activated char-
coal when delayed absorption and added value by 
interrupting enterohepatic cycling is expected [8]. 
Thirdly, digoxin-speci"c Fab fragments have proven 
e#ective in the context of plant intoxications. 
However, higher doses and more frequent administra-
tions were given indicating a probable lower e#ective-
ness than in medicinal digoxin intoxications [2,3,5].
Key points
? Medicinal and vegetal cardiac glycoside poison-
ing produce similar symptoms and toxicity, but 
show important diagnostic and therapeutic 
di#erences.
? Activated charcoal should be considered a soon 
as possible (preferably within two hours, but also 
after expiration of this time). Multiple dose acti-
vated charcoal (MDAC) is recommended in order 
to interrupt intestinal absorption and enterohe-
patic cycling.
? Digoxin assays exhibit variable cross reaction with 
other vegetal cardiac glycosides rendering them 
unuseful to estimate the ingested amount, but 
may be used qualitatively.
? Digoxin-speci"c Fab fragments remain the most 
e#ective measure to reduce life-threatening 
arrhythmias and mortality, though the optimal 
dosage in vegetal intoxications remains unclear.
? Digoxin assays have no place in follow-up of the 
antidotal e#ect of Fab-fragments.
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